指南与共识肝肾功能剂量调整治疗药物监测与药物基因组学

危重患者接受CVVHDF时头孢他啶-阿维巴坦的稳态血药浓度与给药建议

Steady-State Ceftazidime-Avibactam Serum Concentrations and Dosing Recommendations in a Critically Ill Patient Being Treated for Pseudomonas aeruginosa Pneumonia and Undergoing Continuous Venovenous Hemodiafiltration.
指南 / 共识 · Pharmacotherapy · 2019-10-31

本文报道一例50岁危重患者因耐多药铜绿假单胞菌肺炎接受头孢他啶-阿维巴坦2.5g每8小时2小时输注,同时进行连续性静脉-静脉血液透析滤过(CVVHDF)。第11剂后测定头孢他啶和阿维巴坦总血清浓度,头孢他啶游离浓度超过4倍MIC时间达100%给药间隔,阿维巴坦游离浓度>1μg/ml时间达100%给药间隔。基于此病例,该给药方案可能适用于接受CVVHDF的危重肺炎患者。

要点

  • CVVHDF患者给予CAZ-AVI 2.5g q8h(2h输注)可达头孢他啶游离浓度>4×MIC(MIC 8μg/ml)100%给药间隔。
  • 阿维巴坦游离浓度>1μg/ml时间达100%给药间隔。
  • 该方案可能适合接受CVVHDF的危重肺炎患者,但需更多数据验证。

核心结论

  • 对于接受CVVHDF的危重肺炎患者,头孢他啶-阿维巴坦2.5g每8小时2小时输注可能合适。

研究设计与样本

  • 病例报告:50岁危重患者,耐多药铜绿假单胞菌肺炎(CAZ-AVI MIC 8μg/ml),接受CVVHDF。
  • 第11剂CAZ-AVI 2.5g(2小时输注,每8小时一次)后0.5、2、4、6小时测定头孢他啶和阿维巴坦总血清浓度。

主要发现

  • 头孢他啶:Cmax 152.39μg/ml,半衰期5.17小时,Vdss 11.51L,清除率1.54L/小时,AUC 1295.38小时·μg/ml。
  • 阿维巴坦:Cmax 35.83μg/ml,半衰期5.92小时,Vdss 12.44L,清除率1.45L/小时,AUC 343.44小时·μg/ml。
  • 头孢他啶游离浓度超过4倍MIC时间达100%给药间隔。
  • 阿维巴坦游离浓度>1μg/ml时间达100%给药间隔。

关键数值与推荐

  • 头孢他啶游离浓度>4×MIC(MIC 8μg/ml)时间100%给药间隔。
  • 阿维巴坦游离浓度>1μg/ml时间100%给药间隔。

临床怎么用

  • 对于接受CVVHDF的危重肺炎患者,可考虑CAZ-AVI 2.5g每8小时2小时输注。
  • 需结合本地MIC和患者具体情况个体化给药。

局限性

  • 单例病例报告,证据级别低。
  • 未采集或测定上皮衬液药物浓度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ceftazidime-avibactam (CAZ-AVI) is a novel intravenous β-lactam/β-lactamase inhibitor combination used in the treatment of multidrug-resistant (MDR) gram-negative infections. Although renal dosing recommendations exist for the medication, limited data are available for dosing in patients receiving continuous renal replacement therapy. In this report, we describe a case in which CAZ-AVI 2.5 g was administered as a 2-hour infusion every 8 hours to a 50-year-old critically ill patient with MDR Pseudomonas aeruginosa (CAZ-AVI minimum inhibitory concentration [MIC] 8 μg/ml) pneumonia who was also receiving continuous venovenous hemodiafiltration (CVVHDF). Total serum concentrations of both ceftazidime and avibactam were measured at ~0.5, 2, 4, and 6 hours after completion of the 2-hour infusion of the 11th dose of CAZ-AVI. Ceftazidime pharmacokinetic parameters were as follows: maximum serum concentration (Cmax ) 152.39 μg/ml, half-life 5.17 hours, volume of distribution at steady state (Vdss ) 11.51 L, clearance 1.54 L/hour, and area under the concentration-time curve (AUC) 1295.38 hour•μg/ml. This regimen achieved free ceftazidime serum concentrations more than 4 times the MIC for 100% of the dosing interval. Avibactam pharmacokinetic parameters were as follows: Cmax 35.83 μg/ml, half-life 5.92 hours, Vdss 12.44 L, clearance 1.45 L/hour, and AUC 343.44 hour•μg/ml, which achieved free avibactam concentrations above 1 μg/ml for 100% of the dosing interval. Higher CAZ-AVI dosing is critical in the treatment of pneumonia due to limited ceftazidime penetration into epithelial lining fluid; however, epithelial lining fluid drug concentrations were not collected or measured. Based on this case report and the available evidence, a dose of CAZ-AVI 2.5 g infused over 2 hours every 8 hours appears to be appropriate for critically ill patients who are being treated for pneumonia and are receiving CVVHDF.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Soukup P, Faust AC, Edpuganti V, et al. Steady-State Ceftazidime-Avibactam Serum Concentrations and Dosing Recommendations in a Critically Ill Patient Being Treated for Pseudomonas aeruginosa Pneumonia and Undergoing Continuous Venovenous Hemodiafiltration. Pharmacotherapy. 2019. PMID: 31596506. doi:10.1002/phar.2338

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。